Skip to main content
. Author manuscript; available in PMC: 2015 Feb 23.
Published in final edited form as: Clin Cancer Res. 2014 Nov 25;21(3):553–560. doi: 10.1158/1078-0432.CCR-14-1380

Figure 1.

Figure 1

FHD study design: part A, monotherapy and dose escalation. Cohorts 1 and 2 continuous dosing (twice daily, BID) and cohorts 3 to 5 of intermittent dosing (twice daily) on 14-day on and 14-day off cycle (28-day cycle). Part B, combination therapy with lomustine (100 to 130 mg/m2) with >3 patients in each dose group. The combination therapy in two cohorts at 160 mg/day (80 mg twice daily) and 300 mg/day (150 mg twice daily) with LY2157299 given intermittently.